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Feasibility of MRI-guided large-core-needle
biopsy of suspiscious breast lesions at 3T
Abstract The feasibility of large-
core-needle magnetic resonance im-
aging (MRI)-guided breast biopsy at 3
T was assessed. Thirty-one suspicious
breast lesions shown only by MRI
were detected in 30 patients. Biopsy
procedureswereperformedina closed-
bore 3-Tclinical MR system on a
dedicated phased-array breast coil with
a commercially available add-on
stereotactic biopsy device. Tissue sam-
pling was technically successful in
29/31 (94%) lesions. Median lesion
size (n=29) was 9 mm. Histopatho-
logical analysis showed 19 benign
lesions (66%) and one inconclusive
biopsy result (3%). At follow-up of
these lesions, 15 lesions showed no
malignancy, no information was avail-
able in three patients and two lesions
turned out to be malignant (one lesion
at surgical excision 1 month after
biopsy and one lesion at a second
biopsy because of a more malignant
enhancement curve at 12-months
follow-up MRI). Nine biopsy results
showed a malignant lesion (31%)
which were all surgically removed. No
complications occurred. MRI-guided
biopsy at 3T is a safe and effective
method for breast biopsy in lesions that
are occult on mammography and
ultrasound.Follow-upMRIat6months
after the biopsy should be performed in
case of a benign biopsy result.
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Introduction
Magnetic resonance imaging (MRI) of the breast is a
promising diagnostic technique with a high sensitivity and a
reasonable specificity for the detection of invasive breast
tumors [1, 2]. Approximately 10% of patients with a
malignant breast lesion detected on mammography has an
additional malignancy that is mammographically and
ultrasonographically occult [3, 4]. When these additional
suspicious breast lesions are detected on MR images,
histopathological analysis is required. MRI-guided tissue
sampling of these “MRI-only lesions” can be accomplished
bymeansof wirelocalizationand surgicalexcision, vacuum-
assisted biopsy, or by large-core-needle biopsy (LCNB) [5].
LCNB has several advantages over wire localization,
including decreased invasiveness, morbidity, and costs [6, 7].
MRI-guided breast biopsy performed at 1.5T, using a 14-
gaugeMRI-compatibleneedle,hasbeenreportedtohave98%
diagnostic accuracy [8]. Some authors do not recommend
MRI-guided core biopsy for lesions <10 mm, because the
results are often inconclusive [6,9]. Nevertheless, the demand
forbiopsyofsuspectsub-centimeterMRI-onlylesionsishigh.
N. H. G. M. Peters (*) .
C. J. G. Bakker . W. P. T. M. Mali .
A. M. Fernandez-Gallardo .
M. A. A. J. van den Bosch
Department of Radiology,
University Medical Center Utrecht,
Heidelberglaan 100, E.01.132,
3584 CX Utrecht, The Netherlands
e-mail: n.peters@umcutrecht.nl
Tel.: +31-88-7556687
Fax: +31-30-2581098
C. Meeuwis
Department of Radiology, Alysis
Zorggroep, Rijnstate Hospital,
Postbus 9555, 6800 TA
Arnhem, The Netherlands
R. van Hillegersberg
Department of Surgery,
University Medical Center Utrecht,
Heidelberglaan 100, G.04.228,
3584 CX Utrecht, The Netherlands
M. E. I. Schipper
Department of Pathology,
University Medical Center Utrecht,
Heidelberglaan 100, H.04.312,
3584 CX Utrecht, The NetherlandsMRI systems operating at high magnetic fields strengths
(e.g., 3T) become increasingly available in the clinical
setting. The possibility of acquiring high-resolution images
in a short period of time, nominates 3-T breast imaging as
a promising alternative to 1.5-T imaging for diagnostic
purposes. The possibility of decreasing MR data acqui-
sition time while retaining an acceptable signal-to-noise
ratio (SNR) and spatial resolution makes high-field MRI
appealing for interventional purposes as well. However, if
breast biopsies were to be performed at 3T, the suscep-
tibility artifact of the needle would become larger and
could complicate accurate tissue sampling. This prompted
us to assess the feasibility of 3-T MRI-guided LCNB of
suspicious nonpalpable breast lesions.
Materials and methods
Patient characteristics
Thirty-one women (mean age: 48 years; range: 29–78) with
32 suspicious breast lesions which were only detected by
MRI (MRI-only) were examined between September 2005
and February 2008. Indications for diagnostic breast MRI
wereproblemsolving(n=11),increasedriskofbreastcancer
(n=7),preoperativestaging(n=3),work-upofanonpalpable
breastlesion(n=5),tumor-positiveaxillarylymphnodewith
negative mammography (n=1), bloody nipple discharge
(n=2) and unknown (n=2). Patients were referred for MRI-
guidedbiopsyfrom ten differenthospitals. Ofthe 32 lesions,
18 lesions were characterized as BI-RADS-MRI III, nine
lesionsasBI-RADS-MRIIVandfourasaBI-RADS-MRIV
lesion. The BI-RADS-MRI classification of one lesion was
unknown. No approval by the ethics board or informed
consent was obtained because the MRI-guided breast
biopsies were not performed in a study setting, but in the
clinical setting. In our country, patients do not have to give
informed consent for a clinical procedure.
MRI-guided biopsy procedure and equipment
Second-look ultrasound was recommended in all patients;
if the lesion could be retrieved on ultrasound images,
ultrasound-guided biopsy was performed; if the lesion was
occult on ultrasound images, MRI-guided biopsy was
performed. MRI-guided biopsies were performed on a 3-T
clinical MR system (Achieva, Philips Healthcare, Best, The
Netherlands). Patients were placed in the prone position in
a dedicated phased-array bilateral breast coil, with the
affected breast in a dedicated breast coil which had an add-
on biopsy device with a medial and lateral compression
plate (Fig. 1) (MRI Devices, Würzburg, Germany). The
biopsy system comprised a gadolinium-filled guiding
marker tube that can be positioned in the feet-head and
anterior-posterior direction along a centimeter scale and
angulated around the feet-head axis from +45° to -45°
degrees. First, fat-suppressed high-resolution T1-weighted
gradient-echo images were acquired after the administra-
tion of 0.1 mmol/kg gadolinium (Magnevist, Bayer-
Schering, Germany) to verify the position of the lesion.
The administration of the contrast agent was delayed as
long as possible during the procedure to avoid vanishing of
the target lesion. The main parameters of this MR sequence
are listed in Table 1. After correct positioning of the marker
tube, the table top was moved out of the bore and local
anesthesia (lidocaine 1%) was administered subcutaneously.
The marker tube was replaced by a 14-gauge sterile biopsy
needle surrounded by a 13-gauge needle holder (Somatex,
Teltow, Germany). The needle and sheath were horizontally
inserted in the breast and advanced towards the lesion. The
position of the needle and sheath were confirmed by using
the fat-suppressed high-resolution T1-weighted gradient-
echo sequence. After correct placement of the biopsy needle
was confirmed, the 14-gauge biopsy gun (Somatex, Teltow,
Germany) was inserted through the sheath and three to five
tissue samples were obtained.
Data collection
Histopathological analysis of the lesions was performed
and lesions were classified in two categories: benign or
malignant. In case of a benign lesion, the images of the
biopsy procedure were re-evaluated to determine whether
the tissue samples were representative. If the samples were
considered not representative, a second biopsy or surgical
excision was performed, based on the level of suspicion of
malignancy and patient preference. Malignant lesions were
surgically removed.
Fig. 1 Stereotactic system for MRI-guided preoperative wire-
localization and breast biopsy. This system consists of a breast coil,
which can be used for diagnostic MRI of the breast, and an add-on
stereotactic device. The breast is compressed by two compression
plates. The system allows angulation of the needle
1640Results
Ofthe32suspiciousMRI-onlylesions,onelesionwasseenon
second-look ultrasound, and was therefore sampled under
ultrasound guidance. In all other cases, MRI-guided biopsy
was performed. In two cases, MRI-guided biopsy was not
feasible: in one patient a 9-mm lesion was located directly
posteriortothemammillaandinanotherpatienta9-mmlesion
was located directly anterior to the thoracic wall (Fig. 2). No
adequate compression could be achieved in the region in
whichthelesionswerelocated,whichmadeintroductionofthe
biopsyneedlenotfeasibleinbothcases.Intheother28patients
with 29lesions, the 3-T MRI-guided LCNB was considered to
be technically successful. The size of the needle artifact was
9.5 mm. A typical example of the acquired images during the
procedure is shown in Fig. 3. None of the procedures hadtobe
interrupted or stopped. No severe side effects were observed.
The ‘MRI-only’ lesion size ranged from 3 to 45 mm with
a median lesion size of 9 mm. Histopathological analysis of
the biopsy samples resulted in 19/29 (66%) benign lesions
(two fibroadenomas, three fibrocystic changes, six hyper-
plasias/adenoses, five normal fibroglandular tissues, one
intramammary lymph node, one lobular carcinoma in situ
(LCIS) and one papilloma) (Table 2). The results of one
biopsy procedure were inconclusive (1/29, 3%). This
lesion was surgically removed, histopathological analysis
showed no malignancy. Follow-up was heterogeneous
(Fig. 4) due to large number of referring hospitals. In
summary, follow-up of the 20 non-malignant biopsies
showed no malignancy in 15 cases and revealed two
malignant lesions: one LCIS lesion was surgically removed
1 month after the biopsy and additional ductal carcinoma in
situ (DCIS) and a small invasive ductal component were
demonstrated during pathological analysis of the lump. The
second case showed a more malignant kinetic enhancement
curveat12-monthsfollow-upMRI.Thelesionswassampled
again and pathology showed an invasive lobular carcinoma.
No follow-up information was available in three patients.
Nine lesions (9/29, 31%) showed malignant pathological
features in the sampled tissue: two ductal carcinomas in situ,
two invasive lobular carcinomas (apart from the lesion
described above), two invasive ductal carcinomas and three
adenocarcinomas (Table 2). All malignant lesions were sur-
gically removed: modified radical mastectomy (n=3), breast
conserving surgery (n=3), unknown type of surgery (n=3).
Discussion
We report our preliminary experience in MRI-guided large-
core-needle breast biopsies using a 3-Tclosed-bore clinical
MRI system. In our patient series, MRI-guided LCNB was
technically successful in 93% of patients (28/30). Two
Table 1 Main scan parameters of the fat-suppressed high-resolution
T1-weighted gradient-echo sequence used for guiding the biopsy
procedure
Biopsy protocol
TE/TR (ms) 1.7/4.5
Flip angle 10°
Fat suppression Waterselective excitation
pulse (PROSET)
Field of view (mm
2) 340×340
Matrix 256×320
Read-out bandwidth (Hz) 1,443
Direction read-out gradient Perpendicular to B0
Effective slice thickness (mm) 2
Number of slices 75
Acquired voxel size (mm
3) 1.09×1.09×2.00
Reconstructed voxel size (mm
3) 1.09×1.09×1.00
Fast imaging Scan percentage 80%,
over contiguous slices
Scan duration (min) 1.24
Fig. 2a, b Two lesions in which
MRI-guided biopsy was not
feasible. a A 9-mm lesion lo-
cated directly posterior to the
mammilla. b A 9-mm lesion
located directly anterior to the
thoracic wall. In both cases the
part of the breast which con-
tained the lesions could not be
adequately compressed
1641lesions could not be sampled since both lesions were
located in a difficultly accessible location in the breast. In
the most proximal and the most distal parts of the breast,
adequate compression is difficult to achieve, which makes
introduction of the biopsy needle not feasible. We advise to
pursue MRI-guided breast biopsies even in these areas of
the breast. If tissue sampling turns out not to be feasible,
follow-up MRI is advised (to assess growth or change in
the dynamic enhancement curve) or surgical excision of the
lesions depending on the level of suspicion of malignancy.
To increase the diagnostic accuracy of tissue sampling of
small breast tumors, vacuum-assisted biopsy systems have
been proposed and are increasingly introduced in clinical
practice. Vacuum-assisted biopsy has great potential in
(MRI-guided) breast biopsy. When vacuum-assisted breast
biopsy is performed, more tissue is sampled compared with
the amount of tissue removed with LCNB. This would
probably outweigh the negative effect of the larger needle
artifact caused by the use of a larger biopsy needle in
vacuum-assisted biopsy. However, vacuum-assisted biopsy
is not available in all institutions yet and, to our knowledge,
no study has directly compared the diagnostic accuracy
of LCNB with a vacuum-assisted biopsy system in a
randomized controlled trial.
We found 19 benign (66%), one inconclusive biopsy
result (3%) and nine (31%) malignant lesions. These
numbers correspond to the 35%, 34% and 25% malignant
lesions reported in comparable studies [8–10]. The studies
by Kuhl et al. [8] and Fisher et al. [9] reported 98% (77/78)
of the biopsy samples to be representative with the use of a
14-gauge needle [8] and 89% (25/28) using an 18- to 22-
gauge biopsy needle [9]. The 97% (28/29) representative
results we found using a 14-gauge core biopsy are
comparable with the results described by Kuhl et al. [8].
In our study, two benign lesions turned out to be malignant
at follow-up. The second lesion was a lobular carcinoma in
Fig. 3a–c Typical example of a biopsy procedure. a Diagnostic
post-contrast T1-weighted image shows suspicious lesion. b Pre-
biopsy image, compressed breast with guiding marker tube at the
same location as the lesion. c The needle is inserted in front of the
lesion; 3-5 samples were obtained. Histology: DCIS
Table 2 Histological results of the lesions, lesion size and details on
the problem cases (FCC fibrocystic change, LCIS lobular carcinoma
in situ, DCIS ductal carcinoma in situ, ILC invasive lobular
carcinoma, IDC invasive ductal carcinoma)
Number
of lesions
Size (mm)
Benign 19 Median: 8 mm
Fibroadenoma 2 11, 20
FCC 3 8, 12, 45
Adenosis/
hyperplasia
6 3, 6, 7, 9, 10, 15
Normal breast
tissue
5 5 ,6 ,7 ,7 ,8
Lymph node 1 7 At 12-month fol-
low-up MRI:
more malignant
enhancement
curve; second bi-
opsy showed ILC
LCIS 1 8 At surgery LCIS,
DCIS and small
invasive ductal
component (3-
4 mm)
Papilloma 1 30
Non-representative 1 10 FCC at surgery
Malignant 9 Median: 11 mm
DCIS 2 18, 35
ILC 2 6, 7
IDC 2 8, 26
Adenocarcinoma 3 6, 11, 30
1642situ, which was surgically removed. One LCIS lesion was
surgically removed, and additional DCIS and a small
(<4 mm) invasive ductal carcinoma were found at histo-
pathological examination of the lump. The other lesion
showed a more malignant kinetic enhancement curve at 12-
months follow-up MRI. Because of the change in lesion
characteristics, the lesion was sampled again and an
invasive lobular carcinoma was found. Given the change
in enhancement characteristics and the relatively long
period of follow-up, it remains unclear whether the lobular
carcinoma developed during follow-up or should be
considered as a missed malignancy. For this reason the
MRI BI-RADS lexicon committee recommend a 6-month
breast-MRI follow-up after MRI-guided biopsy.
Currently, only one study has been published on breast
imaging at high field strength: Kuhl et al. [8] reported a
prospective intra-individual comparative study performed
on 37 patients with 53 enhancing breast lesions who
underwent contrast-enhanced breast MRI at 1.5T and 3T.
The high resolution of the 3-T images allowed depiction of
lesion morphology with unprecedented accuracy [11],
suggesting a promising role for 3-T breast MRI. In this
patient series, we used 14-gauge titanium biopsy needles.
Large-core needles (14-gauge) are recommended for
percutaneous biopsy of breast lesions to ensure sampling
of sufficient tissue [12]. However, larger needles cause
larger susceptibility artifacts on MR images. Furthermore,
susceptibility artifacts increase with increasing field
strength. This can cause a substantial signal void around
the 14-gauge biopsy needle when performing MRI-guided
breast biopsy at 3T, especially when the biopsy needle is
placed perpendicular to the main magnetic field, as is
usually the case in MRI-guided breast biopsy [9]. Our
study showed that a signal void of 9.5 mm can be achieved
at 3T. To our knowledge, no reports on MRI-guided
breast biopsies at 3T are available. The extent of the
signal void of comparable studies were 4 mm (1.5T, 14-
gauge needle) [8], 5 mm (0.5 T, 16-gauge needle) [9]a n d
10 mm (ultra-fast scan protocol) [9], which is smaller
than the signal void we found at 3T, as was expected.
However, the 9.5-mm signal void did not reduce the
accuracy of the tissue sampling. The previously men-
tioned studies reported a diagnostic accuracy of 98%
(58/59) [8]. Fisher et al. [9] did not report the diagnostic
accuracy of their patient series.
In conclusion, MRI-guided 14-gauge core-needle biopsy
at 3T is a safe and effective method for breast biopsy in
lesions that are occult on mammography and ultrasound.
In the case of benign biopsy results, a 6-month follow-up
MRI should be performed.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
Fig. 4 Flow chart of MRI-guided biopsy lesions and follow-up
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